Literature DB >> 22208487

Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene.

Debra F Saxe1, Diane L Persons, Daynna J Wolff, Karl S Theil.   

Abstract

CONTEXT: Fluorescence in situ hybridization (FISH) is a molecular cytogenetic assay that is commonly used in laboratory medicine. Most FISH assays are not approved by the US Food and Drug Administration but instead are laboratory-developed tests that use analyte-specific reagents. Although several guidelines exist for validation of FISH assays, few specific examples of FISH test validations are available in the literature.
OBJECTIVE: To provide an example of how a FISH assay, using an analyte-specific reagent probe, may be validated in a clinical laboratory.
DESIGN: We describe the approach used by an individual laboratory for validation of a FISH assay for mixed lineage leukemia (MLL) gene.
RESULTS: Specific validation data are provided illustrating how initial assay performance characteristics in a FISH assay for MLL may be established.
CONCLUSIONS: Protocols for initial validation of FISH assays may vary between laboratories. However, all laboratories must establish several defined performance specifications prior to implementation of FISH assays for clinical use. We describe an approach used for assessing performance specifications and validation of an analyte-specific reagent FISH assay using probes for MLL rearrangement in interphase nuclei.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22208487     DOI: 10.5858/arpa.2010-0645-SA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Reply to Chou et al 'Do significant TFE3 gene rearrangements occur in succinate dehydrogenase deficient renal cell carcinoma? Borderline FISH results should be interpreted with caution' Mod Pathol 2017; in press.

Authors:  Sean R Williamson; David J Grignon; Anna Calió; Bradley A Stohr; John N Eble; Liang Cheng
Journal:  Mod Pathol       Date:  2017-10       Impact factor: 7.842

2.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

3.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

Review 4.  Cancer cytogenetics: methodology revisited.

Authors:  Thomas S K Wan
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

5.  One-fits-all pretreatment protocol facilitating Fluorescence In Situ Hybridization on formalin-fixed paraffin-embedded, fresh frozen and cytological slides.

Authors:  Shivanand O Richardson; Manon M H Huibers; Roel A de Weger; Wendy W J de Leng; John W J Hinrichs; Ruud W J Meijers; Stefan M Willems; Ton L M G Peeters
Journal:  Mol Cytogenet       Date:  2019-06-17       Impact factor: 2.009

6.  Role of cytogenetic abnormalities detected by fluorescence in situ hybridization as a prognostic marker: Pathogenesis & clinical course in patients with B-chronic lymphocytic leukaemia.

Authors:  Dhanlaxmi Shetty; Hemani Jain; Yogita Rohil; Navin Khattry; Manju Sengar; Bhausaheb Bagal; Hasmukh Jain; Anant Gokarn; Sachin Punatar; Venkata Naga Avinash Bonda; P G Subramanian
Journal:  Indian J Med Res       Date:  2021-04       Impact factor: 2.375

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.